Advances in Cancer Biomarkers

Advances in Cancer Biomarkers_ From biochemistry to clinic for a critical revision ( ).pdf

Dublin Core


Advances in Cancer Biomarkers




At present, there are a growing number of biomolecules under investigation
to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to
clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some
patients may be simply monitored in their course by a periodic blood sample, but sometimes this monitoring show dramatic limits. A lot of patients
show serious and extensive relapses without significant change in serum
concentrations of biomarkers tested. Often the physician who should utilize
these biomarkers does not entirely know their limits and the total potential
applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and “polluted” knowledge
may have dramatic consequences for patient. A critical approach towards
old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time can facilitate the research
of new and more sensitive-specific signals of the cancer cell proliferation


Roberto Scatena
Institute of Biochemistry and Clinical Biochemistry
School of Medicine, Catholic University
Rome , Italy






© Springer Science+Business Media Dordrecht 2015
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or
part of the material is concerned, specifically the rights of translation, reprinting, reuse of
illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way,
and transmission or information storage and retrieval, electronic adaptation, computer software,
or by similar or dissimilar methodology now known or hereafter developed.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this
publication does not imply, even in the absence of a specific statement, that such names are
exempt from the relevant protective laws and regulations and therefore free for general use.
The publisher, the authors and the editors are safe to assume that the advice and information in
this book are believed to be true and accurate at the date of publication. Neither the publisher nor
the authors or the editors give a warranty, express or implied, with respect to the material
contained herein or for any errors or omissions that may have been made.









Text Item Type Metadata



Original Format




Roberto Scatena Institute of Biochemistry and Clinical Biochemistry School of Medicine, Catholic University Rome , Italy, “Advances in Cancer Biomarkers,” BMU, accessed May 20, 2022,

Output Formats